ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P ASX 200
7,968.20
0.60%
S&P ASX All Technology
3,399.00
0.55%
Brent Oil
65.57
0.34%
US Dollar vs AUD
1.5637
-0.47%
Bitcoin
93,592.99
-0.16%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Anavex Life Sciences Corporation (AVXL) Share Price

Anavex Life Sciences Corporation

Anavex Life Sciences Corporation (AVXL)

NASDAQ
9.47
0.16
( 1.72% )
Updated: 02:14:54
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
9.47
Bid
9.46
Offer
9.48
Volume
122,238
9.27 Day's Range 9.5822
3.25 52 Week Range 14.4405
Market Cap
805.558M
Previous Close
9.31
Open
9.31
Last Trade
200
@
9.47
Last Trade Time
02:14:54
Financial Volume
US$ 1,152,801
VWAP
9.4308
Average Volume (3m)
1,081,584
Shares Outstanding
85,064,199
Dividend Yield
-
PE Ratio
-18.64
Earnings Per Share (EPS)
-0.51
Revenue
-
Net Profit
-43M

About Anavex Life Sciences Corporation

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are u... Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.anavex.com
Headquarters
Carson City, Nevada, USA
Founded
-
Anavex Life Sciences Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AVXL. The last closing price for Anavex Life Sciences was US$9.31. Over the last year, Anavex Life Sciences shares have traded in a share price range of US$ 3.25 to US$ 14.4405.

Anavex Life Sciences currently has 85,064,199 shares in issue. The market capitalisation of Anavex Life Sciences is US$791.95 million. Anavex Life Sciences has a price to earnings ratio (PE ratio) of -18.64.

Ask ADVFN Intelligence (AI)

AVXL Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
03 April 2025
AVXL (1.72%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
03 April 2025
AVXL (1.72%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
03 April 2025
AVXL (1.72%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
13 February 2025
AVXL (1.72%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.667.491486946658.819.88.616699229.10000842CS
40.080.8519701810449.399.867.26511646968.57474858CS
12-0.36-3.662258392689.8310.27.26510815848.74060536CS
264.0775.37037037045.414.44055.2215002549.35208023CS
525.76155.256064693.7114.44053.2512255927.61387455CS
156-0.07-0.7337526205459.5415.243.2512127258.28407362CS
2606.11181.8452380953.3631.53.05135264010.81681061CS

AVXL - Frequently Asked Questions (FAQ)

What is the current Anavex Life Sciences share price?
The current share price of Anavex Life Sciences is US$ 9.47
How many Anavex Life Sciences shares are in issue?
Anavex Life Sciences has 85,064,199 shares in issue
What is the market cap of Anavex Life Sciences?
The market capitalisation of Anavex Life Sciences is USD 791.95M
What is the 1 year trading range for Anavex Life Sciences share price?
Anavex Life Sciences has traded in the range of US$ 3.25 to US$ 14.4405 during the past year
What is the PE ratio of Anavex Life Sciences?
The price to earnings ratio of Anavex Life Sciences is -18.64
What is the reporting currency for Anavex Life Sciences?
Anavex Life Sciences reports financial results in USD
What is the latest annual profit for Anavex Life Sciences?
The latest annual profit of Anavex Life Sciences is USD -43M
What is the registered address of Anavex Life Sciences?
The registered address for Anavex Life Sciences is 701 S CARSON ST, STE 200, CARSON CITY, NEVADA, 89701
What is the Anavex Life Sciences website address?
The website address for Anavex Life Sciences is www.anavex.com
Which industry sector does Anavex Life Sciences operate in?
Anavex Life Sciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TOIIWOncology Institute Inc
US$ 0.182
(191.14%)
234.86k
OMEXOdyssey Marine Exploration Inc
US$ 0.9037
(112.19%)
121.29M
CEPCantor Equity Partners Inc
US$ 28.00
(69.70%)
35.35M
AREBAmerican Rebel Holdings Inc
US$ 4.265
(38.93%)
66.58M
TMCTMC the Metals Company Inc
US$ 3.4403
(34.91%)
32.74M
GNLNGreenlane Holdings Inc
US$ 0.01595
(-93.51%)
242.85M
JZXNJiuzi Holdings Inc
US$ 2.24
(-69.73%)
492.33k
OCEAOcean Biomedical Inc
US$ 0.011
(-46.34%)
71.47M
AGMHAGM Group Holdings Inc
US$ 0.0419
(-27.76%)
24.56M
NCNANuCana PLC
US$ 0.65828
(-26.04%)
480.01k
DMNDamon Inc
US$ 0.00355
(-13.41%)
250.92M
GNLNGreenlane Holdings Inc
US$ 0.01595
(-93.51%)
242.85M
LRHCLa Rosa Holdings Corporation
US$ 0.1581
(29.48%)
157.33M
CNEYCN Energy Group Inc
US$ 0.1491
(17.31%)
149.48M
OMEXOdyssey Marine Exploration Inc
US$ 0.9037
(112.19%)
121.29M

AVXL Discussion

View Posts
sab63090 sab63090 5 minutes ago
BAR123
I'm glad you mentioned this unusual behavior in the stock trading!

I've been thinking that something or that news is pending, yet impressed that the price momentum did not have a quick drop just based on the short term overhead supply (we've been trading right under that area of 10 to 10.50)...and again as Citrati pointed out hesitating under the 200 Week SMA which is about a 4 year hurdle! We did briefly break that level (14. to 14.50) in the prior 4 to 5 months.

Quiet trading yet holding up is frustrating and not especially indicative of where we go from here....but I remain bullish since at the last LOW we broke $8 and then reversed...a classic set up for a continuing uptrend....traders know its name: Turtle Soup
👍️0
Steady_T Steady_T 16 minutes ago
Precision medicine is a description of a process that is used to determine the usefulness of a drug or treatment for a specific person or group of people based on some measurable selection characteristic.

An example is a type of chemo therapy for triple negative breast cancer. That treatment only is useful for persons that have the triple negative genetic profile in their cancer cells. The specific treatment doesn't work well for other forms of breast cancer. So, a genetic test is run on the cancer cells to determine if the treatment is appropriate for the patient, i.e a precision application of the treatment.

In Anavex's case it was thought that the wild type vs the mutated type of the Sigma 1 gene may be a selection criteria for treatment. Subsequent trial data shows that the mutant type gene subjects did not respond as strongly to 2-73 but did respond well enough that they could be included in the standard treatment protocols.
👍️0
Doc328 Doc328 34 minutes ago
In clinical practice 'precision medicine' implies that the choice of treatment or the dose of treatment was based on more unique objective characteristics of the patient rather than just the clinical presentation. The best examples are in oncology. For example if the biopsy pathology shows HER2 positive patterns then Herceptin or Perjeta are more likely to be of benefit. Similar for many cancers (i.e. EGFR in lung Ca; BRAF for melanoma). Less use in neurology. In AD, lecanemab has more risk for E4/E4 patients so that is tested to guide therapy. In MS, data shows anti-CD20 or NAT are more effective for aggressive disease base don MRI characteristics and relapse frequency/ . Biomarkers like NfL or GFAP might also inform as to whether patient is receiving a benefit from current therapy.

For A273, one could imagine, if borne out in a larger study, lack of the S1R Q2P mutation and lack of the Col24A variant might one day be used to determine candidacy for treatment. Precision medicine is not used as a term in regards to how well the drug targets its receptor.
👍️ 1
Hoskuld Hoskuld 43 minutes ago
That is my interpretation, too. All mAbs, all GPCRs, most drugs period, hit the same receptors over and over. The effects differ from person to person and even in a single person over time - despite the specificity of the interactions.
👍️0
Hoskuld Hoskuld 45 minutes ago
There is basically no such thing as precision medicine in a differentiated sense. It is, of course, not personalized medicine either.

Dr. Gabelle was doubtless not the author of that blurb.
👍️0
dia76ca dia76ca 48 minutes ago
Some think an Anavex buyout might be at more than $200 a share?

Any calculation must include Worldwide sales of Blarcamesine to treat early Alzheimer's. But it must also include its early use in preventing Alzheimer's. And it must also include its use against Parkinson's ,Rett and several other indications.

And any buyout would include Anavex 3-71 which has shown activity against Schizophrenia, Alzheimer's and Frontotemporal Dementia. In fact both Blarcamesine and A3-71 may be active against dozens of CNS diseases!

It is not an exaggeration to say that in a few years Anavex will become the world leader in the treatment of Central Nervous System diseases!

IMO any Big Pharma who wants to buyout Anavex will have to pay multiples of $200 to even be considered!
👍 1 👍️ 2
tschussmann1 tschussmann1 51 minutes ago
Hoskuld, replying to: "precision medicine" is an empty marketing term. mAbs are precise. AChEIs are precise. Every GPCR and every mAb is precise. Even chemotherapy is precise. What exactly do you think "precision medicine" is?

From my Deming days, precision means to hit the same location repeatedly. Accuracy would be to hit the correct location. Presumably blarcamesine is accurate enough in terms of which receptor(s) is(are) targeted to have an impact on Alzheimer's disease. Precision could mean that the drug activates the targeted receptor(s) and not others. Precision could also mean that the response does not have the negative side effects of drugs such as the mabs. It would be interesting to get the official answer from Anavex.
👍 1
longtermbeliever longtermbeliever 59 minutes ago
let them borrow your shares no need to worry.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
👍 1
longtermbeliever longtermbeliever 1 hour ago
all friends of mine been adding massively in the last two weeks.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
👍️ 1
longtermbeliever longtermbeliever 1 hour ago
24M shorty humm we may have a early fireworks this year.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
👍️ 1
ignatiusrielly35 ignatiusrielly35 1 hour ago
Dark pool trades are indeed reported to FINRA and appear in the ticker in quasi-real time (a slight delay). The market in which the trade occurred is blacked out, i.e. is not identified. Obviously, then, the trades are also accounted for in the reported volume. So tutes are not secretly acquiring large positions that are not reflected in the reported trading. 
👍️ 1
Investor2014 Investor2014 1 hour ago
https://www.fda.gov/medical-devices/in-vitro-diagnostics/precision-medicine
👍️0
xodcode xodcode 1 hour ago
"precision medicine" is an empty marketing term. mAbs are precise. AChEIs are precise. Every GPCR and every mAb is precise. Even chemotherapy is precise. What exactly do you think "precision medicine" is?

My point is simply that I seem to recall much discussion with the theme that Anavex has nothing to do with precision medicine. Obviously as posted previously Prof. Gabelle would dispute that assertion.
👍 2
rx7171 rx7171 2 hours ago
Adding dementia couldn’t have been an accident.
Although I doubt if it opens the door automatically to other dementias beyond AD it hints at an express lane becoming available for future applications in other dementias,
IF approved for AD.

Off label use by physicians will be very tempting if not too expensive since cost will not be covered by insurers.
The company may give a discount in such cases.
👍️ 2
subluxed subluxed 2 hours ago
With the May 10 calls having an open interest of 2,100 contracts, I wouldn't be surprised to see the share price capped out under $10 at least until they expire. But one never knows???
🎯 1 👍️ 1
Hoskuld Hoskuld 2 hours ago
"precision medicine" is an empty marketing term. mAbs are precise. AChEIs are precise. Every GPCR and every mAb is precise. Even chemotherapy is precise. What exactly do you think "precision medicine" is?
👍️0
subluxed subluxed 2 hours ago
Shorts are not giving up. A friend of mine just told me that Fidelity borrowed more shares today @ 6.75% interest.
What's it going to take for them to cover?
Partner?
Approval?
Pass the 1st stop questions?
👍 3
hnbadger1 hnbadger1 2 hours ago
There are over 100 types of dementia including PDD!
👍️ 2
Lacey1 Lacey1 2 hours ago
How do naked shorts play into this? Naked shorts have used non revenue biotechnology stocks as revenue sources for decades. Legal theft like money center banks printing money.
👍️0
BAR123 BAR123 2 hours ago
So what is everyone's thoughts on the low vol. Do the tutes have all they want at this point in time or is there just no more interest from them and they are awaiting for a sign from the EMA. I guess a sign would be a passing mark on the 120 day clock stop questions which could be in the June timeframe with all questions answered satisfactorily. Or it could be something positive from the FDA. Or a partnership.

But what do you all think of the low vol? I am hopeful that we see at least 50% tute ownership but would love to see it up to 60% which would kill the shorts.
👍️ 3 😃 1
tschussmann1 tschussmann1 2 hours ago
Do dark pool trades show as trading volume during the day, at market close (including MOC?), later after market close, or not at all? From what I have read, it seems that dark pool and private trading is on the increase. Might institutions acquire many of their shares off market?
👍️0
subluxed subluxed 2 hours ago
The submission to EMA was for ALZ and Dementia. Dementia covers a lot of other indications besides ALZ.
👍️ 2 😃 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 3 hours ago
the MAA mentions both AD and Dementia.

Interesting. I wonder if an PDD trial results are included in the application?

A broad approval would be an EPIC event - Triple figure stock price in weeks

Maybe also a potential compromise? Approval for alz, run a p3 for parkinsons?
👍️ 6 😃 1
LakeshoreLeo1953 LakeshoreLeo1953 3 hours ago
I think THAT is actually the learning moment for those here who think they do.
👍️ 1 😃 1
k9uwa k9uwa 3 hours ago
Very probable you are correct Leo. MM's need inventory.

as an Add ON yesterday all 3 major indexes did somewhat the same as Anavex. Up quickly after the open and through the day gradual decline. Net for the day was positive for all three Dow Nasdaq S&P500
John k9uwa
👍️0
Investor2014 Investor2014 3 hours ago
The $VIX has only spiked higher than in the last few weeks once, which was the 2008 credit crunch.

No record yet for the current administration, but I have no doubt they are working on it.
👍️0
k9uwa k9uwa 4 hours ago
Wish I had an answer to that one Leo. a few scared shorts buying their way out? Or a few that wanted IN. Just because the major indexes were well UP. It would
have been a great day for perhaps the few that sold near that peak and bought back later in the day... Damned if I know... My Crystal Ball not working well these days.
John k9uwa
👍️0
LakeshoreLeo1953 LakeshoreLeo1953 4 hours ago
Unsure if you wish to paint the shorts as
learned or timely.
👍 1
LakeshoreLeo1953 LakeshoreLeo1953 4 hours ago
NO argument with Market forces and there bias.
Point of contention is a polite disagreement that
MOC is Tute accumulation.
IMHO it is much more skewed to MM balancing than
outright buy signal from Insty(s).
👍️ 2 😃 1
LakeshoreLeo1953 LakeshoreLeo1953 4 hours ago
My question spoke to the first hour of trading yesterday as it was
seemingly the unwarranted "pop".
It seems failed at this point down $1+ from high.
That volume was similar to any MOC computed.

As to pre Market....I never give a shite.
👍️0
Investor2014 Investor2014 4 hours ago
Once we see the label if A2-73 is approved, we will know if its a one size fits all or a more specific to the individual's biology precision medicine.

Things like APOE alle types, Sigma-1 Wt. or either, perhaps Collagen Genetics etc. from whatever subgroup responder analysis done.

Alternatively, we'll get to know when the design of confirmatory trial is revealed.
👍️ 1
Investor2014 Investor2014 5 hours ago
Well there you have it! - who needs Blarcamesine then?

👍️ 1
xodcode xodcode 5 hours ago
Prof. Gabelle:
I am committed to leveraging my experience, and to supporting the Anavex Life Sciences Company’s ambition of improving lives through novel precision medicine such as blarcamesine.”

I could have sworn that we were told by some on this board that "precision medicine" and Anavex was an oxymoron! Hmmm!
🎆 3 🏆️ 5 👍️ 11 😃 1
k9uwa k9uwa 5 hours ago
Ahead of the open only a couple thousand shares. On Open maybe 10K ... as to tutes gaining on May 15th will find out what they did Jan1-Mar31 I Predict they
will be above the 35% shown for Q4 of last year.
John k9uwa
👍 2
sab63090 sab63090 7 hours ago
ignatiusrielly35
Yes, I agree that the shorts do not want this to push up past that $10 to $10.50 area which was also a prior high, just back in March and was a reason that I suggested that level as a reasonable target a while back.

Additionally, as Citrati mentioned in his post yesterday it was also the resistance 200 WEEKLY SMA (that's a 4 year area of resistance)....it was broken when the price broke that level hitting the $14 to $14.50 level in December and January, but then failed and we dropped back to lows under $8. We have resumed the uptrend and the picture has improved.

I'm feeling that both the fundamental and technical picture are looking good...but we've just got to get some volume along with a strong push UP!
👍️ 2 😃 1
Hoskuld Hoskuld 11 hours ago
All companies pursuing promising AD therapies have SABs with competent members with good reputations. This is not in and of itself significant.

If this alone, of all your stocks, is being shorted then none of the others are pre-revenue biotech companies.
👍️ 2
Investor2014 Investor2014 11 hours ago
There are eminent scientists on the SAB of many biotech companies that fail with a drug that looked promising.
👍️ 1
HomerRomer HomerRomer 11 hours ago
Can anyone (including the fudsters) paint me a picture of a world where Dr. Gabelle would put her reputation on the line joining this board and make glowing comments about Blarcamesine if she truly thought after all of her research that AVXL was bogus and likely to fail to get EMA approval? My confidence in approval is now at 99% and I believe Dr. Gabelle's (who has been privied to all of the behind the scenes details) is even more confident...I only put my money at risk, but one's reputation is much more valuable.

Another impressive vote of confidence and addition to the already impressive AVXL boards/teams. Looking at the credentials of everyone who liked and commented on her LinkedIn post she made (about her appointment to the AVXL Scientific Advisory board) is a great reminder that with every strong team member comes additional connections, pull, credibility, and oportunities to succeed at a higher rate and efficiency.
👍️ 20 💯 4
HomerRomer HomerRomer 12 hours ago
<img class="img-fluid" alt="" src="//investorshub.advfn.com/uimage/uploads/2025/4/24/gggqy1745468491012.jpg" width="500">Out of all the stocks in my portfolio, the only one Fidelity is interested in borrowing is AVXL.  Short squeeze is emanant...just need one nugget of news to ignite!
👍 7
tredenwater2 tredenwater2 16 hours ago
Upon (accelerated) approval by the EMA for AD the new Trump Fda appointee needs to make our drug a priority for review. Get the dang “revisited”Act that Ted Cruz is pushing passed and start the clock. The way things work in the good ol’ USA, it will be two years out after the EMA approves us.

And I dont buy that BP isnt influencing the decisions downtown otherwise Makery would not be pushing them out.
👍️ 15 😀 3
ignatiusrielly35 ignatiusrielly35 16 hours ago
The short interests have been protecting their position for a long time. Read: short hedges and mm's. They do not want, in particular, any long momentum traders to start playing in the sandbox. 
👍️ 5 😀 2
LakeshoreLeo1953 LakeshoreLeo1953 18 hours ago
Does the theory hold then that
The Open was bought by FOMO Retail
and the close by Tutes?
Similar Volumes. Dissimilar pricing.
After the first hour shenanigans things definitely retraced.

I guess it could be Tutes got exuberant @ open AND close.
Has anyone bothered to total MOC volume over the last Q
and match against Insty holdings?

Not sure it is a meaningful exercise, but might be enlightening.
👍️0
LakeshoreLeo1953 LakeshoreLeo1953 18 hours ago
As Fire Season approaches in America's National Forests
I can only hope to renew Satphone Service so I can benefit from
the BEST trader I have EVER encountered.
Haleakala is a distant second.

WGT has nothing on revisionist posters.
👍️0
frrol frrol 18 hours ago
She's a KOL in Europe, good to see she is supportive of our drug for AD.
👍️ 1
mike_dotcom mike_dotcom 19 hours ago
You know we'll give all the gains back tomorrow. It's the law.
👍️ 1
k9uwa k9uwa 20 hours ago
30 seconds before the Bell 887k shares traded. Jumped to 962K at 4:00 so 75K MOC order today.
Mike at least we kept a DIME above yesterday's close.

John k9uwa
👍️ 4
crescentmotor crescentmotor 20 hours ago
Expect well over 1 million shares of AVXL to be bought today!!!

Wrong for two days (probably more--I didn't look) in a row. I was actually rooting for you Georgie but your personality invites bad karma.
👍️ 4
crescentmotor crescentmotor 20 hours ago
I also do think everything is as normal with Georgejjl - he will be dependably wrong again today.


Yup--Georgie is consistently wrong--no easier call than that.
👍️ 4 😃 1
tredenwater2 tredenwater2 21 hours ago
While the new SAB member’s PR only talks about AD the MAA mentions both AD and Dementia.

I wonder if PDD would be included as well as other forms of dementia?

This is right up Professor Dr. Gabelles wheelhouse in early diagnoses and prevention. It has continual prophylactic use written all over it.
👍️ 11 😃 2
mike_dotcom mike_dotcom 21 hours ago
We can and we will. It was just another great SELLING opportunity. You can ALWAYS sell this dogschitt on any little pop. And that's all we ever get - a little pop and then the selling kicks in.
👍️0

Your Recent History

NASDAQ
AVXL
Anavex Life Sciences
Delayed Upgrade Clock
ADVFN Logo
Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads